Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma

BACKGROUND: Glioblastoma (GBM) is refractory to immune checkpoint inhibitor (ICI) therapy. We sought to determine to what extent this immune evasion is due to intrinsic properties of the tumor cells versus the specialized immune context of the brain, and if it can be reversed. METHODS: We used CyTOF...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonds, Erin F, Lu, Edbert D, Badillo, Oscar, Karimi, Shokoufeh, Liu, Eric V, Tamaki, Whitney, Rancan, Chiara, Downey, Kira M, Stultz, Jacob, Sinha, Meenal, McHenry, Lauren K, Nasholm, Nicole M, Chuntova, Pavlina, Sundström, Anders, Genoud, Vassilis, Shahani, Shilpa A, Wang, Leo D, Brown, Christine E, Walker, Paul R, Swartling, Fredrik J, Fong, Lawrence, Okada, Hideho, Weiss, William A, Hellström, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183210/
https://www.ncbi.nlm.nih.gov/pubmed/34083417
http://dx.doi.org/10.1136/jitc-2020-002181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183210/
https://www.ncbi.nlm.nih.gov/pubmed/34083417
http://dx.doi.org/10.1136/jitc-2020-002181

Ejemplares similares